Chevy Chase Trust Holdings LLC Reduces Stake in DaVita Inc. (NYSE:DVA)

Chevy Chase Trust Holdings LLC decreased its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 11.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 26,368 shares of the company's stock after selling 3,513 shares during the quarter. Chevy Chase Trust Holdings LLC's holdings in DaVita were worth $4,323,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Cinctive Capital Management LP bought a new position in shares of DaVita in the third quarter valued at approximately $10,093,000. Benjamin Edwards Inc. purchased a new stake in DaVita in the 3rd quarter valued at $207,000. Atom Investors LP bought a new position in DaVita during the 3rd quarter valued at $4,094,000. Erste Asset Management GmbH purchased a new position in DaVita during the 3rd quarter worth $454,000. Finally, Maverick Capital Ltd. grew its stake in shares of DaVita by 11.5% in the 3rd quarter. Maverick Capital Ltd. now owns 12,886 shares of the company's stock worth $2,112,000 after acquiring an additional 1,333 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.

Insider Activity

In other news, CEO Javier Rodriguez sold 9,881 shares of DaVita stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $162.85, for a total value of $1,609,120.85. Following the completion of the transaction, the chief executive officer now owns 887,835 shares in the company, valued at $144,583,929.75. This trade represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.00% of the company's stock.

Analyst Upgrades and Downgrades

DVA has been the topic of several analyst reports. Truist Financial boosted their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a report on Monday, October 7th. Barclays boosted their target price on DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $161.80.

DaVita Stock Performance

DVA stock traded down $1.12 during mid-day trading on Friday, hitting $160.25. The company had a trading volume of 506,762 shares, compared to its average volume of 744,634. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The firm has a market cap of $13.14 billion, a PE ratio of 17.29, a price-to-earnings-growth ratio of 0.92 and a beta of 0.90. DaVita Inc. has a 12 month low of $103.40 and a 12 month high of $169.51. The stock's fifty day moving average price is $158.58 and its two-hundred day moving average price is $150.23.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same period last year, the firm posted $2.85 EPS. The company's revenue for the quarter was up 4.6% compared to the same quarter last year. On average, analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.